Antibiotic Resistance in Klebsiella pneumoniae and Related Enterobacterales: Molecular Mechanisms, Mobile Elements, and Therapeutic Challenges
Antibiotics · 01.01.2026 · 15 (1) · 37
DOI: 10.3390/antibiotics15010037 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Antibiotics, online erschienen am 01.01.2026. Verfasst von Veronika Zdarska und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 3, 77515 Olomouc, Czech Republic. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 218 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education, Youth and Sports of the Czech Republic (MŠMT), Palacký University Olomouc, National Institute of Virology and Bacteriology.
Abstract (Originalsprache)
Drug-resistant Klebsiella pneumoniae and related Enterobacterales represent an escalating global public health threat, increasingly limiting therapeutic options in both healthcare- and community-associated infections. This review summarizes how resistance in K. pneumoniae emerges from the synergy of intrinsic barriers and acquired determinants. Key molecular mechanisms include reduced permeability via porin remodeling (notably OmpK35/OmpK36), multidrug efflux (e.g., AcrAB-TolC and OqxAB), and enzymatic drug inactivation driven by extended-spectrum beta-lactamases and carbapenemases (e.g., KPC, OXA-48-like enzymes, and metallo-beta-lactamases). We also highlight clinically meaningful pathways underlying polymyxin/colistin resistance, including mgrB inactivation and PhoPQ/PmrAB-mediated lipid A modification. In addition to stable genetic resistance, adaptive programs can shape transient tolerance and persistence, including stress responses that modulate gene expression under antibiotic and host-imposed pressures. The ability of these organisms to form biofilms, particularly on medical devices, further complicates treatment and eradication. Finally, we discuss therapeutic implications and current options and limitations—including novel beta-lactam/beta-lactamase inhibitor combinations and siderophore cephalosporins—and emphasize the importance of aligning therapy and surveillance with the underlying resistance mechanisms and circulating high-risk lineages.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Microbiology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 3, 77515 Olomouc, Czech Republic.
- Laboratory of Medical Microbiology and Virology, University Hospital of Varese, 21100 Varese, Italy.
- Department of Medicine and Technological Innovation, University of Insubria, 21100 Varese, Italy.
ORCID-Profile: Veronika Zdarska, Gabriele Arcari, Milan Kolar, Patrik Mlynarcik
Förderung
- Ministry of Education, Youth and Sports of the Czech Republic (MŠMT)
- Palacký University Olomouc
- National Institute of Virology and Bacteriology
- European Union—Next Generation EU, and the Internal Grant Agency of Palacky University
Zitieren
APA
Zdarska, V., Arcari, G., Kolar, M., & Mlynarcik, P. (2026). Antibiotic Resistance in Klebsiella pneumoniae and Related Enterobacterales: Molecular Mechanisms, Mobile Elements, and Therapeutic Challenges. Antibiotics, 15(1), 37. https://doi.org/10.3390/antibiotics15010037
Vancouver
Zdarska V, Arcari G, Kolar M, Mlynarcik P. Antibiotic Resistance in Klebsiella pneumoniae and Related Enterobacterales: Molecular Mechanisms, Mobile Elements, and Therapeutic Challenges. Antibiotics. 2026;15(1):37. doi:10.3390/antibiotics15010037
BibTeX
@article{Zdarska2026,
author = {Zdarska, Veronika and Arcari, Gabriele and Kolar, Milan and Mlynarcik, Patrik},
title = {Antibiotic Resistance in Klebsiella pneumoniae and Related Enterobacterales: Molecular Mechanisms, Mobile Elements, and Therapeutic Challenges},
journal = {Antibiotics},
year = {2026},
volume = {15},
number = {1},
pages = {37},
doi = {10.3390/antibiotics15010037}
}
EUVIMED